Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
41 Cards in this Set
- Front
- Back
|
Breast Cancer Screening
|
Females 20-30s = CBE q 3 years
>40= mamograpy yearly and CBE yearl Self breast exams encouraged starting in 20s Patients with family history= genetic testing, MRI, or early mammograms may be considered |
|
|
Colorectal Cancer Screening
|
Men and Women> 50 yrs = sigmoidoscopy, CT scan, barrium enema q 5 yrs or colonoscopy q 10 years
AND a fecal occult blood test, fecal immunochemical test, or stool DNA test yearly |
|
|
Cervical Cancer Screening
|
starting at age 21 years,
21-29 yrs = PAP test every 3 years 30 -65= PAP and HPV test every 5 years or PAP every 3 years >65 years with all normal cervical cancer test results do not need testing |
|
|
Prostate Cancer Screening
|
Provide screening info to men >50
- info may be provided earlier to men with FH, and african americans PSA with or without a digital rectal exam is standard screening measure |
|
|
Define Response
Partial Response Stable disease and Progression |
R- no disease for 1 month
PR- >50% reduction in tumor size SD- less thatn 25% reduction in tumor P- >25% growth of tumor or growth into new site |
|
|
Neoadjuvant/ induction therapy
|
tx used prior to start of primary regimen to shrink tumor initially
|
|
|
Adjuvant therapy
|
tx give after primary tx in attempt to eradicate residual disease
|
|
|
CHemo Dosing and BSA
What is the Formula |
SQR ROOT [(height in cm x weight in kg)/3600]
|
|
|
Gosrelin**
|
Zoladex
LHRH agonist (Leutenizing Hromone Releasing Hormone) and is an anti androgen |
|
|
Histrelin
|
Vantos
LHRH agonist (Leutenizing Hromone Releasing Hormone) and is an anti androgen |
|
|
Leuprolide**
|
Lupron (IM), Eligard (SC), Viadur (SC)
LHRH agonist (Leutenizing Hromone Releasing Hormone) and is an anti androgen |
|
|
Triptorelin
|
Trelstar
LHRH agonist (Leutenizing Hromone Releasing Hormone) and is an anti androgen |
|
|
LHRH agonist
Use, MEchanism, SE, monitor |
Prostate CA in males
endometriosis, fibroids, annd breast cancer in females *** initially increases androgens/ and estrogens followed by down regulation thhrough negative feedback of gonadotropin release, LH and FSH ****** So a estrogen or androgen antagonist needs to be started 1 week prior to these agents to prevent tumor flare ***Hot flashes, bone pain, impotence, injection site pain, dyslipidemia, QT prolongation, gynecomastia, and peripheral edema ***Monitor DEXA , supplement CA and vit D |
|
|
Bicalutamid**
|
Casodex
50mg po qd Androgen Receptor Blocker |
|
|
Flutamide
|
Eulexin
250mg po q8h Androgen Receptor Blocker |
|
|
Nilutamide
|
Nilandron
Androgen Receptor Blocker |
|
|
Antrogen Receptor Blockers
-use and SE |
Prostate cancer usually given with LHRH agonist
- hot flash, DNV, gynecomastia, hepatotoxicity impotence **night blindness with nilutamide, and more GI upset with flutamide |
|
|
abiraterone acetate
Brand MOA SE |
zytiga 5mg po BID or 10mg QD
*pregnenolone analog that ireversibly inhibits CYP c17 inhibitor--> the reate limiting enzyme in androgen production in the testes, adrenals, and prostate * hypokalemia, HTN, fluid retention ** TAKE ON EMPTY STOMACH |
|
|
Enzalutamide
|
Xtandi
- used in castration resistant metastatic prostate cancer - receptor signaling pathway inhibitor |
|
|
Degarelix
|
Firmagon
GRH antagonist -similar efficacy to LHRH agonist but doens't cause tumor flare |
|
|
Anastrozol**
|
Arimidex
1mg po QD -Breast cancer -aromatase inhibitor |
|
|
Exemestane
|
Aromasin
25mg po QD -Breast cancer -aromatase inhibitor |
|
|
Letrozole
|
Femara
2.4 mg po QD -Breast cancer -aromatase inhibitor |
|
|
Aromatase Inhibitor
- MOA - USE -SE |
prevents conversion to active estrogne/ androgen/ corticosteroid, miineralocorticode
- APPROVED in POST MENOPAUSAL WOMEN - osteoprosis, hotflashes, althragia -with or without food |
|
|
Fluvestrant**
|
Faslodex
500mg IM day 1, 15. 29, then monthly - Estrogen REceptor Antagonist |
|
|
Raloxifene**
|
Evista
60mg po QD SERM |
|
|
Tamoxifen**
|
Nolvadex
20mg po QD SERM ***CYP 2DG *4 and *5 polymorphism results in shorter disease free survival ***Caution with 3A4, 2D6, and 2C9 DDI |
|
|
Toremifene
|
farestron
SERM |
|
|
SERMs and ERB
|
-selectively blocks estrogen at receptor sige
- CA in hormone receptor positive tumors in post menopausal women ( except tamoxifen indicated for pre and post menopausal women and men) -BBW for increased risk of thromboembolic events -SE--cataracts, and endometrial cancer risk increases - improve osteoprosis and hyperlipidemia (escept fluvestrant) |
|
|
Anthracycline
|
-Topoisomerase II inhibition, free radical , alkylator
- red color, may cahnge secretions - SE: myelosupression, alopecia, mucocytis, cardiac toxicity, extravasation, tadiation recall reactions occur - |
|
|
dexrazoxane
|
zinecard- cardioprotective agent used with anthracyclines
- |
|
|
Daunorubicin
|
Cerubidine
- MLD=450-550mg/m2 (or 450 with radiation) Anthracycline |
|
|
Daunorubicin liposomal
|
DaunoXome
Anthracycline |
|
|
Doxorubicin**
|
Adriamycin
MLD- 550mg/m1 (or 400 with radiation) Anthracycline |
|
|
Epirubicin
|
Ellence
900mg/m2 Anthracycline |
|
|
Idarubicin
|
Idamycin
150mg/m2 Anthracycline |
|
|
What side effect is decreased and increased by liposomal formulationsof anthracyclines
|
cardiac toxcitiy is decreased but hand foot syndrome is worsened
|
|
|
Mitoxantrone
|
Noantrone
- MLE-mg/m2 Anthracenedione, turns body fluid blue |
|
|
Valrubicin
|
Valstar- instilled into bladder for bladder cancer
|
|
|
What can be used to help with anthracycline extravasation?
|
Totec (dexrazoxane)
Cold compress OR DMSO |
|
|
Lenalidomide (Revlimid )**
and Thalidomide (Thalomid) |
oral med
MDS and multiple myeloma RevAssist program or STEPS Program -Revlimid is less sedating, less thromboembolic events, (ASA vs Warfarin) |
